Is adagrasib effective in controlling disease?

Adagrasib, trade nameKrazati, is a targeted therapy drug targeting the KRAS G12C mutation. KRAS gene mutations are key driver mutations in a variety of malignant tumors, especially in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). In recent years, adagrasib, as a specific inhibitor of KRAS G12C mutation, has been gradually recognized for its anti-cancer effect.

Adagrasib specifically binds to the KRAS G12C mutation site and inhibits the function of this gene, thereby preventing cancer cell proliferation and metastasis. This mechanism makes it an effective treatment for KRAS G12C mutant cancers, especially in patients for whom conventional chemotherapy and immunotherapy have failed.

In clinical trials, adagrasib demonstrated significant anti-tumor effects. According to clinical data, patients taking adagrasiib showed better results in terms of disease control rate, progression-free survival (PFS) and overall survival (OS). Adagrasiib can effectively shrink tumors and slow down disease progression, especially in patients with KRAS G12C mutations, showing good disease control.

However, the therapeutic efficacy of adagrasib also varies depending on the patient's specific condition and drug resistance. In some patients, drug resistance may develop over time, and therefore, the effect of adagrasib will be limited.

In general, adagrasib has a good disease control effect on patients with KRAS G12C mutated non-small cell lung cancer and colorectal cancer, especially when other treatments are ineffective, providing a new treatment option for patients. To ensure maximum effectiveness, use of adagrasib generally requires individualized evaluation and monitoring.

Reference materials：https://www.krazati.com/